Get notified of page updates
Treatment for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor
Clinicaltrials.gov identifier:NCT06065059
Study Contact Information:
Study of a New Treatment Called TNG348 in People with Advanced or Metastatic Cancer and with a BRCA1 or BRCA2 Mutation or HRD Positive Tumor
Treatment for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor
Clinicaltrials.gov identifier:NCT06065059
Study Contact Information:
Glossary on
off
About the Study
This study is no longer recruiting patients.
The study will test the safety and effectiveness of a new drug called TNG348 used alone or in combination with (a .) The study is for patients who have advanced breast, ovarian, pancreatic, and cancer and a or mutation or have an positive tumor.
This Study is Open To:
This study is no longer recruiting patients.
This Study is NOT Open To:
This study is no longer recruiting patients.
Study Contact Information: